



Louisiana

Retired Policy

Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Ovarian Cancer

Policy # 00810

Original Effective Date: 01/01/2023

Retired Date: 07/01/2024

Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Ovarian Cancer was retired effective 07/01/2024.

A retired medical policy is no longer active and is not utilized for coverage eligibility determination or claims processing as of the retired date.

This medical policy is being retired as a part of the collaborative partnership with Carelon MBM Genetic Testing Program. Carelon will provide genetic testing management services to ensure enforcement of genetic testing policies effective 07/01/2024.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.